Mark Cziraky, PharmD, CLS: The Future of Biosimilars

Video

Mark Cziraky, PharmD, CLS, describes what he sees as the future of the biosimilars space.

Transcript:

What do you see as the future for the biosimilar space?

Well, I think a big part of it is we’re hopeful that these therapies become a big opportunity to reduce costs in the healthcare system while getting the intended benefits of these therapies.

You look at the generic marketplace and biopharmaceuticals in general, and while it’s taken some time, there are significant cost savings to be appreciated from using generic therapies. So, if you apply that to the biosimilar marketplace, and hopefully we’ll see again significant cost-reductions in the acquisition costs in the use of these therapies, and we’ll see benefits in that area too.

Related Videos
Legal scale weighs profit as greater than medical treatment
Ha Kung Wong, JD.
Ha Kung Wong, JD
Cencora's Corey Ford
Brian Biehn
Chelsee Jensen, PharmD, BCPS
Ryan Haumschild, PharmD, MS, MBA
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.